Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-alpha prime. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-alpha prime. Methods of using these compounds for modulation of Casein kinase 2-alpha prime expression and for treatment of diseases associated with expression of Casein kinase 2-alpha prime are provided.
Claims What is claimed is: 1. A compound 20 to 50 nucleobases in length targeted to nucleobases 21 through 51 or nucleobases 56 through 95 of a 5'-untranslated region, nucleobases 180 through 237, nucleobases 251 through 280, nucleobases 285 through 316, nucleobases 393 through 468, nucleobases 479 through 641, nucleobases 646 through 686, nucleobases 707 through 736, nucleobases 750 through 769, nucleobases 872 through 891, nucleobases 950 through 969, nucleobases 978 through 997, nucleobases 1004 through 1045, nucleobases 1056 through 1075, nucleobases 1099 through 1118, nucleobases 1146 through 1165, or nucleobases 1184 through 1203 of a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule encoding Casein kinase 2-alpha prime of SEQ ID NO: 3, or a coding region, a stop codon region or a 3'-untranslated region of a nucleic acid molecule encoding mouse Casein kinase 2-alpha prime of SEQ ID NO: 10, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of Casein kinase 2-alpha prime. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. A compound up to 50 nucleobases in length comprising at least a 20-nucleobase portion of SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 623, 64, 65, 66, 67, 68, 69, 70, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 93, 94, 95, 72 or 82 which inhibits the expression of Casein kinase 2-alpha prime. 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage. 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11 further comprising a colloidal dispersion system. 13. The composition of claim 11 wherein the compound is an antisense oligonucleotide. 14. A method of inhibiting the expression of Casein kinase 2-alpha prime in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of Casein kinase 2-alpha prime is inhibited. 15. The compound of claim 3 which is an antisense oligonucleotide. 16. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 24. The composition of claim 23 further comprising a colloidal dispersion system. 25. The composition of claim 23 wherein the compound is an antisense oligonucleotide. 26. A method of inhibiting the expression of Casein kinase 2-alpha prime in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 3 so that expression of inhibiting the expression of Casein kinase 2-alpha prime is inhibited. 